We are live on ! Find out more
EOLS icon

Evolus

172 hedge funds and large institutions have $539M invested in Evolus in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 50 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,954% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $587K

28% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 50

5.4% more ownership

Funds ownership: 85.34%90.74% (+5.4%)

4% less funds holding

Funds holding: 179172 (-7)

13% less funds holding in top 10

Funds holding in top 10: 87 (-1)

17% less capital invested

Capital invested by funds: $653M → $539M (-$114M)

18% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 34

Holders
172
Holders Change
-7
Holders Change %
-3.91%
% of All Funds
2.26%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.09%
New
28
Increased
64
Reduced
50
Closed
34
Calls
$12.1M
Puts
$587K
Net Calls
+$11.5M
Net Calls Change
+$10.1M

EOLS Hedge Fund Activity: Q2 2025 in Review

172 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Evolus (EOLS) for Q2 2025, worth a combined $539M — down 17% from $653M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of EOLS and 28 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 64 added.

The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $24.9M. The largest seller was Perceptive Advisors, cutting an estimated $16.9M.

  • 172 institutional investors held Evolus (EOLS) as of Q2 2025, down from 179 in Q1 2025.
  • Funds reported $539M of Evolus stock for Q2 2025, down 17% quarter-over-quarter.
  • 28 funds opened new Evolus positions in Q2 2025 and 34 closed out, a net change of -6 holders.
  • The largest Evolus buyer in Q2 2025 was Frazier Life Sciences Management, an estimated $24.9M added.
  • The largest Evolus seller in Q2 2025 was Perceptive Advisors, an estimated $16.9M sold.

Based on aggregated 13F filings for Q2 2025.